Upregulated PI3K/AKT/mTOR signaling, the occurrence of mutational changes in the PI3K pathway and emerging clinical data from trials with PI3K inhibitors make PI3K an attractive target for cancer therapy, particularly in patients with recurrent/metastatic HNSCC. This evidence concerns the gene PIK3CA and cancer.